Latest "Zenobia Therapeutics" News Stories - Page: 3

00:03 EDT 19th September 2018 | BioPortfolio

Here are the most relevant search results for "Zenobia Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Zenobia Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Zenobia Therapeutics for you to read. Along with our medical data and news we also list Zenobia Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Zenobia Therapeutics Companies for you to search.

Showing "Zenobia Therapeutics" News Articles 51–75 of 7,800+

Probably Relevant

Abeona Therapeutics Inc: Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease

NEW YORK and CLEVELAND, April 20, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene ther...

Summit Therapeutics plc: Director/PDMR Shareholding

Summit Therapeutics plc ('Summit', the 'Company', or the 'Group')Director / PDMR Share DealingOxford, UK, Cambridge, MA, US, 16 July - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), announces ...

Repros Therapeutics (RPRX) Set to Announce Earnings on Thursday

Repros Therapeutics will release its earnings data before the market opens on Thursday, March 29th. Analysts expect Repros Therapeutics to post earnings of per share for the quarter.

Novartis plans digital therapeutics for schizophrenia and MS

Will work with Pear Therapeutics on a prescription software range

Arcturus Therapeutics Achieves Program Milestones and Refines Agreement with Cystic Fibrosis Foundation Therapeutics

SAN DIEGO, July 23, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ:ARCT), a leading RNA medicines company, today announced the achievement of key milestones as part of its agreement with Cystic Fibrosis Foundation (CF Foundation) Therapeutics, Inc. The completion of these success-driven milestones has triggered an undisclosed payment to Arcturus from the CF Foundation to advance LU...

Rubius Therapeutics to Acquire Manufacturing Facility in Smithfield, Rhode Island to Produce Red Cell Therapeutics

CAMBRIDGE, Mass., July 25, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies, today announced that it has signed a purchase and sale agreement for the acquisition of a 135,000-square foot manufacturing facility located in Smithfield, Rhode Island. The company plans to invest up t...

Evox Therapeutics raises new funds to support drug development

UK-based therapeutics developer Evox Therapeutics has secured $45.4m in a series B financing round to support new drug development. The...Read More... The post Evox Therapeutics raises new funds to support drug development appeared first on Pharmaceutical Technology.

The Current issue of “The view from here” is concerned with Novel Therapeutics.

The topic of this month’s newsletter from Drug Discovery Today is Novel Therapeutics.

The Current issue of “The view from here” is concerned with Therapeutics

The topic of this month’s newsletter from Drug Discovery Today is “Therapeutics”

In The Spotlight: PTC Therapeutics

Shares of PTC Therapeutics Inc. (PTCT) have gained as much as 24% so far this month while the iShares Nasdaq Biotechnology ETF index (IBB) is up just 8.6% for the same period.

Lilly's Olumiant Makes Big Leap In Lupus Trial

A couple of weeks after the setback of getting a worse-than-expected label from the FDA for Olumiant in rheumatoid arthritis...   

Rubius Therapeutics brings in new CEO

Rubius Therapeutics, a biotech that has ambitions to bring “super blood” to the market, has revealed that it has appointed a new CEO to lead the company. Pablo Cagnoni enters the position, joining the biotech from Tizona Therapeutics, which he led as CEO. He joins the company not long after its second successful financing round, after the company raised $100 million in March. read more

PTC Therapeutics FOPO brings in $102.5mm

PTC Therapeutics Inc. (rare disease and cancer therapeutics) netted $102.5mm through the public offering of 4mm shares at $27...

Antibe Therapeutics Looking for More Licensing Deals

Antibe Therapeutics is trying to change the game of non-steroidal anti-inflammatory drugs (NSAID)—the “largest category of drugs globally,” CEO Dan Legault told INN. The post Antibe Therapeutics Looking for More Licensing Deals appeared first on Investing News Network.

Transition Therapeutics licenses drug candidate from Eli Lilly

Transition Therapeutics announced its wholly-owned subsidiary, Transition Therapeutics Ireland Limited, has exclusively licensed worldwide rights to a novel small molecule drug candidate ("TT701") from Eli Lilly and Company. TT701 is a selective androgen receptor modulator that has been shown in a Phase 2 study to significantly increase lean body mass and a measurement of muscle more » The post T...

Apricus Biosciences Announces Merger Agreement with Seelos Therapeutics

Apricus Biosciences (NASDAQ:APRI) has announced it has signed an agreement to merge with Seelos Therapeutics in an all-stock transaction. As quoted in the press release: The merged company will focus on the development and commercialization of central nervous system (CNS) therapeutics with known mechanisms of action in areas with a highly unmet medical need. Upon … Continued The post Apricus...

Can Digital Therapeutics Substitute for Drugs or Other Therapies?

The various smart phone apps that are being developed to monitor or help manage diseases like diabetes or insomnia are now being referred generally as digital therapeutics (see: Can “Digital Therapeutics” Be as Good as Drugs?). This article provocatively asks the question whether some of these apps can ultimately substitute...

Topas Therapeutics GmbH: Topas Therapeutics and Boehringer Ingelheim Sign Multi-Year Collaboration and Option Agreement

Companies join forces in immune tolerance to tackle ADA (anti-drug antibodies) Initial focus on next generation vector-based therapeutics Boehringer Ingelheim is granted option to in-license sever...

Roche To Use Lodo Therapeutics' Drug Discovery Platform

NewsUnder the terms of the agreement, Genentech will utilize Lodo Therapeutics’ proprietary genome mining and biosynthetic cluster assembly platform to identify novel molecules with therapeutic potential against multiple disease-related targets of interest to Genentech.

Silence Therapeutics chief executive Mortazavi steps down

RNA therapeutics developer Silence Therapeutics announced on Monday that its chief executive Ali Mortazavi will leave the company with immediate effect after a six year stay. Silence said that unti...

In The Spotlight: G1 Therapeutics

Shares of G1 Therapeutics Inc. (GTHX) have returned an impressive 103% year-to-date while the iShares NASDAQ Biotechnology Index (ETF)(IBB) is up a paltry 2.8% during the same period.

Lilly pays $63mm up front for rights to Sigilon's living therapeutics technology

Sigilon Therapeutics Inc. granted Eli Lilly & Co. exclusive global rights to its Afibromer living therapeutics technology for...

Sandoz, Pear to commercialize prescription digital therapeutics

Sandoz, a division of Novartis, and Pear Therapeutics have agreed to jointly commercialize and continue development of novel prescription digital therapeutics designed to treat disease and improve clinical outcomes for patients.

Genentech, Lodo Therapeutics form $969m drug discovery collaboration

Roche’s subsidiary Genentech has entered into a strategic drug discovery collaboration with Lodo Therapeutics, which is focused on the creation of therapeutics derived from nature that will impact patients across the world.

Third Rock Ventures Launches Cedilla Therapeutics to Target Protein Stability Using Small Molecule Therapeutics

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cedilla Therapeutics, a new biotechnology company broadening the reach of small molecule therapeutics by discovering and exploiting unique insights into protein stability, launched today with $56.2 million in Series A funding from Third Rock Ventures. Cedilla is leveraging a growing understanding of the principles that dictate protein stability and appl...

Quick Search


News Quicklinks